Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Pfizer Profits Unexpectedly Rise 9%

August 4, 2010 6:37 am | by Linda A. Johnson | News | Comments

Pfizer Inc. reported a 9 percent rise in second-quarter profit, trouncing Wall Street expectations as revenue jumped 58 percent due to favorable currency rates and its mega-acquisition of fellow drugmaker Wyeth last October.

TOPICS:

FDA Stepping Up Oversight of Medical Devices

August 4, 2010 6:33 am | by Matthew Perrone | News | Comments

Makers of X-ray machines, drug pumps and other medical devices would have to submit more safety information to win federal approval under a proposal designed to tighten regulation of thousands of products reviewed each year.

TOPICS:

Genotyping Array

August 3, 2010 8:37 am | Product Releases | Comments

Affymetrix, Inc. announced that it will develop and commercialize the Axiom Chinese myDesign Genotyping Array, the first product that provides maximum power for genome-wide association studies specifically on Chinese populations.

TOPICS:
Advertisement

Multiplexing Instrument

August 3, 2010 8:32 am | Product Releases | Comments

Luminex Corporation announced the global launch of MAGPIX, an analytical instrument that is capable of performing up to 50 tests on a single sample and providing nearly 5,000 data points in under an hour.

TOPICS:

Telormedix Studying TMX-201 For Malaria

August 3, 2010 8:26 am | News | Comments

Telormedix announced the start of a collaboration with the Swiss Tropical and Public Health Institute (Swiss TPH) on a pilot study using Telormedix’s adjuvant, TMX-201, in connection with immunization for malaria and Buruli ulcer.

TOPICS:

Cornerstone Licenses Patents to Targacept

August 3, 2010 8:20 am | News | Comments

Cornerstone Therapeutics Inc. announced that it has licensed to Targacept, Inc. the worldwide rights to its nicotinic-receptor based patents and library of preclinical compounds that target the alpha-7 or other nicotinic receptors.

TOPICS:

Researchers Debate The Meaning of Cured

August 3, 2010 8:15 am | News | Comments

In patients with non-small cell lung cancer (NSCLC), five-year disease-free survival is currently the benchmark of cure. However, there are two issues that remain with the follow-up standards: When can cure be declared with confidence and how long should follow-up examination be continued?

TOPICS:

LBL Scientists Detail How Enzyme Breaks Down Proteins

August 3, 2010 8:11 am | News | Comments

Scientists have obtained the closest look yet of how a gargantuan molecular machine breaks down unwanted proteins in cells, a critical housekeeping chore that helps prevent diseases such as cancer.

TOPICS:
Advertisement

Daiichi Sankyo And ArQule Partner On Lung Cancer Drug

August 3, 2010 8:04 am | News | Comments

ArQule, Inc. and Daiichi Sankyo Co., Ltd. announced that they will move forward with a Phase 3 clinical trial of ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase, in patients with non-small cell lung cancer.

TOPICS:

FDA Issues IND for Trabedersen

August 3, 2010 7:59 am | News | Comments

The biopharmaceutical company Antisense Pharma announced that the US-American Food and Drug Administration (FDA) has issued an Investigational New Drug (IND)-authorisation for clinical studies with trabedersen for patients with high-grade glioma.

TOPICS:

Bayer Q2 Earnings Drop 1.3%

August 3, 2010 7:55 am | News | Comments

Germany's Bayer AG saw second-quarter net earnings slip by 1.3 percent as a stronger revenue was offset by one-time charges for lawsuits and writing down a cancer drug.

TOPICS:

Amgen Income Down 5%

August 3, 2010 7:45 am | News | Comments

Biotechnology company Amgen Inc. that its second-quarter net income slipped 5 percent, mainly on higher taxes, but the results topped Wall Street expectations.

TOPICS:

AstraZeneca Posts Profit Increase of 22%

August 3, 2010 7:43 am | by Jane Wardell | News | Comments

AstraZeneca PLC doubled its share buyback program after posting strong second quarter results and revealing that a key new drug - its blood thinner Brilinta - has been given a thumbs up by an advisory committee of the U.S. Food and Drug Administration.

TOPICS:

Shire Offering $566M for Movetis

August 3, 2010 7:40 am | News | Comments

Movetis NV has received a conditional offer from a subsidiary of Shire plc, the global specialty biopharmaceutical company, to acquire all outstanding shares and warrants of Movetis NV for €428 million.

TOPICS:

PerkinElmer Buys VisEn

August 3, 2010 7:22 am | News | Comments

PerkinElmer, Inc., a global business focused on the health and safety of people, announced that it has acquired VisEn Medical, Inc., an in vivo molecular imaging technology company.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading